Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MaxCyte, Inc. stock logo
MXCT
MaxCyte
$1.25
+6.8%
$1.25
$0.64
▼
$1.81
$120.80M1.491.47 million shs975,795 shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MaxCyte, Inc. stock logo
MXCT
MaxCyte
+6.84%+13.64%-3.85%-9.42%-26.90%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MaxCyte, Inc. stock logo
MXCT
MaxCyte
$1.25
+6.8%
$1.25
$0.64
▼
$1.81
$120.80M1.491.47 million shs975,795 shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MaxCyte, Inc. stock logo
MXCT
MaxCyte
+6.84%+13.64%-3.85%-9.42%-26.90%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
MaxCyte, Inc. stock logo
MXCT
MaxCyte
2.00
Hold$4.50260.00% Upside

Current Analyst Ratings Breakdown

Latest LLAI, IDHC, DMTR, and MXCT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/12/2026
MaxCyte, Inc. stock logo
MXCT
MaxCyte
Set Price Target$4.00
11/4/2026
MaxCyte, Inc. stock logo
MXCT
MaxCyte
DowngradeSell (D-) ➝ Sell (E+)
10/22/2026
MaxCyte, Inc. stock logo
MXCT
MaxCyte
UpgradeSell (E+) ➝ Sell (D-)
10/6/2026
MaxCyte, Inc. stock logo
MXCT
MaxCyte
DowngradeSell (D-) ➝ Sell (E+)
9/22/2026
MaxCyte, Inc. stock logo
MXCT
MaxCyte
UpgradeSell (E+) ➝ Sell (D-)
9/8/2026
MaxCyte, Inc. stock logo
MXCT
MaxCyte
DowngradeSell (D-) ➝ Sell (E+)
8/25/2026
MaxCyte, Inc. stock logo
MXCT
MaxCyte
UpgradeSell (E+) ➝ Sell (D-)
8/24/2026
MaxCyte, Inc. stock logo
MXCT
MaxCyte
Reiterated RatingNeutral
(Data available from 11/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
MaxCyte, Inc. stock logo
MXCT
MaxCyte
$33.03M3.91N/AN/A$1.46 per share0.86
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
MaxCyte, Inc. stock logo
MXCT
MaxCyte
-$44.63M-$0.26N/AN/AN/A-81.40%-15.05%-12.79%N/A

Latest LLAI, IDHC, DMTR, and MXCT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/10/2026Q3 2026
MaxCyte, Inc. stock logo
MXCT
MaxCyte
-$0.0775-$0.05+$0.0275-$0.05$7.39 million$8.16 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
MaxCyte, Inc. stock logo
MXCT
MaxCyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
MaxCyte, Inc. stock logo
MXCT
MaxCyte
N/A
7.83
7.37

Institutional Ownership

CompanyInstitutional Ownership
MaxCyte, Inc. stock logo
MXCT
MaxCyte
68.81%

Insider Ownership

CompanyInsider Ownership
MaxCyte, Inc. stock logo
MXCT
MaxCyte
4.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
MaxCyte, Inc. stock logo
MXCT
MaxCyte
91103.25 million99.02 millionOptionable

Recent News About These Companies

MaxCyte (NASDAQ:MXCT) CEO Buys 100,000 Shares of Company Stock
MaxCyte (MXCT) Q3 2026 Earnings Call Transcript
MaxCyte Q3 Earnings Call Highlights
MaxCyte (MXCT) Expected to Release Quarterly Earnings on Tuesday
MaxCyte stock quote holds at EUR 1.53 late on October 29
MaxCyte, Inc. (MXCT) Q2 2026 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

MaxCyte stock logo

MaxCyte NASDAQ:MXCT

$1.25 +0.08 (+6.84%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$1.36 +0.11 (+8.72%)
As of 05:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.